PAEDIATRIC LYMPHOMA: A COMPREHENSIVE REVIEW OF TREATMENT OPTIONS

Edwin Dias* and Clelia K. B.

ABSTRACT

Pediatric lymphoma is a diverse group of malignancies that account for approximately 10% of childhood cancers.
It is a highly treatable malignancy, with cure rates including 80% for many subtypes. This review offers a thorough
overview of the current classification system, staging criteria, and treatment approaches for pediatric lymphoma.
Hodgkin's and non-Hodgkin's lymphoma are the two main categories of lymphoma. A distinctive type of
lymphoma known as Hodgkin lymphoma is distinguished by the presence of Reed-Sternberg cells and the
histopathologic characteristics of Hodgkin lymphoma cannot be distinguished from non-Hodgkin lymphoma, a
heterogenous group of lymphoid neoplasms that can arise from mature or immature (lymphoblastic) natural killer
cells, T-cells, or B-cells. This review encompasses the revised International Paediatric Non-Hodgkin Lymphoma
Staging System (IPNHLSS), the Ann Arbor staging system, the St. Jude system, and the World Health Organization
(WHO) classification system. It also covers treatment options such as radiation therapy, chemotherapy,
immunotherapy, stem cell transplantation, and new agents like CAR-T cell therapy.

Keywords: Hodgkin lymphoma, non-Hodgkin lymphoma, world health organization (WHO), CAR-T cell therapy, Reed-Sternberg cells, natural killer cells, T-cells, B-cells.